LYPD1 and neoplasm: To investigate the antitumor efficacy of bivalent anti-LYPD1 TCBs in comparison to monovalent anti-LYPD1 TCBs, we used the immunodeficient NOD SCID gamma mouse (NSG) with human PBMCs delivered by adoptive transfer 14 days prior to implantation of the LYPD1-expressing tumor cells.